Literature DB >> 17574312

Salmonella enterica serovar Typhimurium strain lacking pmrG-HM-D provides excellent protection against salmonellosis in murine typhoid model.

Vidya Devi Negi1, Santanu Singhamahapatra, Dipshikha Chakravortty.   

Abstract

The superiority of live attenuated vaccines in systemic salmonellosis has been proven over killed and subunit vaccines, because of its ability to induce protective cell mediated immunity by CD8+ T cells. A live attenuated Salmonella enterica serovar Typhimurium vaccine has been developed by systematic site directed deletion of the pmrG-HM-D chromosomal genomic loci. This gene confers involved in antimicrobial peptide resistance and is involved in LPS modification, both of which are the major immune evasive mechanisms in Salmonella. The efficacy of the newly developed strain in inducing protection against mortality after challenge with the virulent wild type Salmonella typhimurium 12023 was evaluated in mice model of typhoid fever. Animals were immunized and then boosted on days 7 and 14. Following challenge with virulent S. typhimurium 12023, organ burden and mortality of vaccinated mice were less compared to non-immunized controls. The vaccine strain also induced elevated CD8+ T cells in the vaccinated mice. This multiple mutant vaccine candidate appears to be safe for use in pregnant mice and provides a model for the development of live vaccine candidates against naturally occurring salmonellosis and typhoid fever.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574312     DOI: 10.1016/j.vaccine.2007.05.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Protective efficacy of a Salmonella Typhimurium ghost vaccine candidate constructed with a recombinant lysozyme-PMAP36 fusion protein in a murine model.

Authors:  Ja Young Moon; So Young Kim; Won Kyong Kim; Zhili Rao; Jung Hee Park; Ji Young Mun; Boram Kim; Hyo Sun Choi; Jin Hur
Journal:  Can J Vet Res       Date:  2017-10       Impact factor: 1.310

2.  Haloarchaeal gas vesicle nanoparticles displaying Salmonella antigens as a novel approach to vaccine development.

Authors:  P DasSarma; V D Negi; A Balakrishnan; J-M Kim; R Karan; D Chakravortty; S DasSarma
Journal:  Procedia Vaccinol       Date:  2015

3.  Needleless vaccine delivery using micro-shock waves.

Authors:  Gopalan Jagadeesh; G Divya Prakash; S G Rakesh; Uday Sankar Allam; M Gopala Krishna; Sandeepa M Eswarappa; Dipshikha Chakravortty
Journal:  Clin Vaccine Immunol       Date:  2011-02-09

4.  Protective efficacy of the recombinant lysozyme-PMAP36 fusion protein-inactivated Salmonella Typhimurium vaccine candidate via oral immunization in a murine model.

Authors:  Jayoung Moon; Soyoung Kim; Wonkyong Kim; Zhili Rao; Junghee Park; Byungyong Park; Jin Hur
Journal:  Can J Vet Res       Date:  2020-07       Impact factor: 1.310

Review 5.  Typhoid fever & vaccine development: a partially answered question.

Authors:  Sandhya A Marathe; Amit Lahiri; Vidya Devi Negi; Dipshikha Chakravortty
Journal:  Indian J Med Res       Date:  2012       Impact factor: 2.375

Review 6.  Gas Vesicle Nanoparticles for Antigen Display.

Authors:  Shiladitya DasSarma; Priya DasSarma
Journal:  Vaccines (Basel)       Date:  2015-09-07

7.  A safe vaccine (DV-STM-07) against Salmonella infection prevents abortion and confers protective immunity to the pregnant and new born mice.

Authors:  Vidya Devi Negi; Arvindhan G Nagarajan; Dipshikha Chakravortty
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

8.  Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice.

Authors:  Vikalp Vishwakarma; Niladri Bhusan Pati; Himanshu Singh Chandel; Sushree Sangeeta Sahoo; Bhaskar Saha; Mrutyunjay Suar
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.